Vaxcyte (PCVX) Assets Average (2020 - 2026)

Vaxcyte (PCVX) has 7 years of Assets Average data on file, last reported at $3.2 billion in Q1 2026.

• Assets Average for Q1 2026 came in at $3.2 billion, down 7.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.2 billion (down 7.81% YoY), and the FY2025 annual result was $3.3 billion, up 32.42% from the prior year.
• Assets Average advanced to $3.2 billion in Q1 2026 per PCVX's latest filing, from $3.1 billion in the prior quarter.
• Over five years, Assets Average peaked at $3.5 billion in Q4 2024 and troughed at $363.5 million in Q1 2022.
• A 5-year average of $2.0 billion and a median of $1.7 billion in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2023 and 2025: Assets Average soared 264.08% in 2023, then decreased 12.68% in 2025.
• A 5-year view of Assets Average shows it stood at $709.1 million in 2022, then jumped by 104.76% to $1.5 billion in 2023, then surged by 143.5% to $3.5 billion in 2024, then declined by 12.68% to $3.1 billion in 2025, then climbed by 2.86% to $3.2 billion in 2026.
• Business Quant data shows PCVX's Assets Average at $3.2 billion in Q1 2026, $3.1 billion in Q4 2025, and $3.2 billion in Q3 2025.